Meropenem B. Braun

Meropenem, the active ingredient in Meropenem B. Braun, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, bacterial meningitis, severe sepsis, septic shock, and hospital‑acquired or ventilator‑associated pneumonia in hospitalized patients.

GNH USA supplies Meropenem B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic indicated for serious infections affecting various organ systems. - Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: clears resistant uropathogens and resolves infection symptoms. - Bacterial meningitis: penetrates the cerebrospinal fluid to eradicate causative bacteria. - Severe sepsis and septic shock: provides rapid bactericidal activity to support hemodynamic recovery. - Hospital‑acquired and ventilator‑associated pneumonia: treats multidrug‑resistant Gram‑negative and Gram‑positive pathogens in critical care settings.

Meropenem, like other carbapenems, may be associated with a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in some patients. - Diarrhea: may be watery and self‑limiting. - Headache: transient headache reported during therapy. - Rash: mild skin erythema or pruritus. - Infusion site phlebitis: local irritation at the IV site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or pre‑existing CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis. - Neutropenia or thrombocytopenia: marked reductions in white blood cells or platelets. - Renal toxicity: worsening kidney function in susceptible individuals.

When using Meropenem, clinicians should consider several safety precautions to minimize risks. - Renal impairment: adjust dose based on creatinine clearance to avoid accumulation. - Hypersensitivity: avoid in patients with known allergy to carbapenems or β‑lactams. - Seizure risk: monitor neurologic status, especially in patients with CNS disorders or high doses. - Pediatric use: dose must be calculated per kilogram body weight under specialist guidance. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Concomitant nephrotoxic drugs: monitor renal function when combined with aminoglycosides or vancomycin. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: carbapenems markedly reduce serum valproate levels, increasing seizure risk. - Co‑administration with other carbapenems: may lead to additive toxicity and is generally unnecessary. - High‑dose aminoglycosides: combined use can exacerbate nephrotoxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics (e.g., furosemide): monitor renal function and electrolytes. - Warfarin: observe INR values as meropenem may potentiate anticoagulant effect. - Probenecid: may increase meropenem plasma concentrations, requiring dose adjustment. - NSAIDs: concurrent use may further impair renal function, especially in at‑risk patients.